Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines based on its VAAST vector-adjuvant-antigen tablet platform. It offers oral enteric-coated tablet vaccine candidates targeting infectious diseases (norovirus, COVID-19, seasonal and avian influenza) and a preclinical therapeutic HPV vaccine, along with royalty interests in licensed antivirals. Its business is organized around vaccine development programs, antiviral royalty holdings and manufacturing/R&D capabilities, including in-house and contract manufacturing for bulk drug substance and tablet formulation. It markets and distributes via clinical trial networks, third-party contract manufacturers, government partnerships and global regulatory pathways.
Summary from filing dated 2025-03-20
Frequently asked questions
What is Vaxart, Inc.'s CIK number?
Vaxart, Inc.'s SEC CIK number is 0000072444 (72444). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Vaxart, Inc.'s SEC filings?
All of Vaxart, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.